{
  "name": "Vicore Pharma Holding",
  "slug": "vicore-pharma-holding",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-05T23:45:48Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-05: stängning 11.18, volym 622923",
  "mfn_status": "resolved_no_reports",
  "mfn_count": 0,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/vicore-pharma-holding/reports",
    "count": 16,
    "nasdaq_count": 16,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-05-06",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Delårsrapport januari - mars 2026",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b00c6b9419fef5bc28396a5eea3441408&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a17a9a42943519ac9b9499fe483dd8fb0",
            "date": "2026-05-06",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "Delarsrapport_Q1_2026.pdf",
            "text_chars": 43334,
            "sha256": "09147e95128f9573312939d88e4cd55ef0f44869b0d6c2e67669fdb18de078a2",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 43334
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-03-26",
        "title": "Årsredovisning 2025",
        "original_title": "Vicore offentliggör årsredovisning för 2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b600d68604b5fc3eac062c3954b408421&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac8734d7900ed05a77157d57e58b8b371",
            "date": "2026-03-26",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "Vicore_Arsredovisning_2025.pdf",
            "text_chars": 264632,
            "sha256": "cf21b11fe94cda4920e011e4e767df699b1349e5f5e2c869b360c68369924dd6",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 177351
              },
              {
                "number": 2,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 87279
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-27",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Bokslutskommuniké 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b72784e8b83c8522ce08632a00a87ef39&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/afd2d355616d2dcdf9003f1247ed96a80",
            "date": "2026-02-27",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "Bokslutskommunike_2025.pdf",
            "text_chars": 48919,
            "sha256": "7e4a990abee0deb5b338104e95f47947087f925b89faba7d499c506c37cc4b57",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 48919
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-11-05",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "Delårsrapport juli-september 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b7db3aa72a81418db70ff496c131bfcc0&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a29e802aad5879985f414115f16438495",
            "date": "2025-11-05",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "Delarsrapport_Q3_2025.pdf",
            "text_chars": 51972,
            "sha256": "0e5199bb265cc9be60565f6340f00d5a45b86ab1b999286b68a23102291bd697",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 51972
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-08-22",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Delårsrapport april-juni 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b97f6d13a90c2672b76c146ae640a80cb&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a601e14263c6a6dcc72f09a601e5b2ca5",
            "date": "2025-08-22",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "Delarsrapport_Q2_2025.pdf",
            "text_chars": 46643,
            "sha256": "4f5e331a70cc9772f9dd39e6df020504fac3d16ca61251bf208d4a16873d736a",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 46643
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-05-06",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Delårsrapport januari-mars 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b3054c17c4a86c0f5b08a02f0e9590b1e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ad1ca81c15c657972c0cbda55b9a6cf97",
            "date": "2025-05-06",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "Delarsrapport_1_Jan_31_Mar_2025.pdf",
            "text_chars": 45176,
            "sha256": "161203666816ea945e02334a7230bae78a4e1ea2e6b137545068c9a8eaa7c3c3",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 45176
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-03-26",
        "title": "Årsredovisning 2024",
        "original_title": "Vicore offentliggör årsredovisning för 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bdd4d68888e865bc214adcdd4677b1d08&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a66794ceb802528c55ffb3b1ee8c7dc30",
            "date": "2025-03-26",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "Vicore_Arsredovisning_2024.pdf",
            "text_chars": 287791,
            "sha256": "e628a6484cb38d6916f50f4bc7eb4107854107a6b4209198279eeffc4e890f83",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 177393
              },
              {
                "number": 2,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 110396
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-27",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Bokslutskommuniké 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b360b480bb9fc49e165fd522b72bf1b42&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae73c8303818455588695b9a0c1a06058",
            "date": "2025-02-27",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "Bokslutskommunike_2024_SWE.pdf",
            "text_chars": 49883,
            "sha256": "d4ea4a7ef8edb2a85eb7b43efde15f54c7399e3b60bc62edffc2942f1effadfd",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 49883
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-11-05",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Delårsrapport juli-september 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba1091d4997b1ad6a448ff25af01915e0&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a5e2cc4eb1aa5dacb7918657cd4a93246",
            "date": "2024-11-05",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "Delarsrapport_Q3_2024.pdf",
            "text_chars": 50324,
            "sha256": "d71acb6909f6dc0064559b9d5eada617dc7a5aa63bb83175f56d6ad761982ba0",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 50324
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-08-22",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "Delårsrapport april-juni 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b8e0088e8cb4bbbc4bdd222a8d48f4385&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac33a252ae1cac6377103173b7acabf2c",
            "date": "2024-08-22",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "Delarsrapport_Q2_2024.pdf",
            "text_chars": 44660,
            "sha256": "b1aba9ecf5644930cba10892b99fbd6453b3cb18fcd3bba129bfe31e5a67ade5",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 44660
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-05-03",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "Delårsrapport januari-mars 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b07abb63329fd21adf8d4a9f2ba0e3bb6&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aacba62192026d1de39a5f33b4daf9986",
            "date": "2024-05-03",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "Delarsrapport_Q1_2024_FINAL.pdf",
            "text_chars": 41479,
            "sha256": "4bb721d5cd96b117a2187fe95d2cbeaeb4ef1620ebcc885308a87e4feba34f5d",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 41479
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-03-27",
        "title": "Årsredovisning 2023",
        "original_title": "Vicore offentliggör årsredovisning för 2023",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bd7b3e65ea8ded43a8959cfcf5981d5eb&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a2ae7c68718235fae332b816f53ab1738",
            "date": "2024-03-27",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "Vicore_Arsredovisning_2023.pdf",
            "text_chars": 269652,
            "sha256": "8cd42f435d0f31bff067af1f3f30fc1a7412f89d76ced868bea0929d79c6716a",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 179110
              },
              {
                "number": 2,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
                "chars": 90540
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-02-28",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "Bokslutskommuniké 2023",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b5cb03fd0542c64e01c883b37cd1f5acd&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ad4f6a640bbf90aa0f94b72149a909dbd",
            "date": "2024-02-28",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "Bokslutskommunike_2023.pdf",
            "text_chars": 45516,
            "sha256": "f652188f84d1a7e121c4fd947d8c3929e298979d50634fa8ca98838242c02eab",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 45516
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-11-02",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "Delårsrapport juli-september 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b2c54299bcf62d6367d586a5c4588c58f&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a0e437a99b9af6d9ca3735b061af97537",
            "date": "2023-11-02",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "Delarsrapport_Q3_2023.pdf",
            "text_chars": 43926,
            "sha256": "3344bafc5252080871c96ece9a38f5b51c9d7b3b10a360129f1a7bef78146d4d",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 43926
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-08-24",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "Delårsrapport april-juni 2023",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b9c1e213206b463347e49c17c1c83df25&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ade8c9e5626a289c75d0d5612b408bc0b",
            "date": "2023-08-24",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "Delarsrapport_April_Juni_2023.pdf",
            "text_chars": 42123,
            "sha256": "fc851ed2d2aaaac8bab7199536d85cdbc693257f10bbf79d95a307b89d767da2",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 42123
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-05-04",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "Rättelse: Delårsrapport januari-mars 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b135579da42267f8c35aef4506d1d7e46&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a4a08c7c7e1a6de7650f7cc53f699d9bf",
            "date": "2023-05-04",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "Delarsrapport_Jan_Mar_2023.pdf",
            "text_chars": 39808,
            "sha256": "8e7ec395406e329278366eab28393e92de4ec1fbc55fc025a82ed1d7356fea5b",
            "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 39808
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 16,
  "nasdaq_report_count": 16,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "Vicore Pharma Holding",
    "identity": {
      "issuer": "Vicore Pharma Holding AB",
      "lei": "549300KTNBPTZLF01130",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 13,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Vicore Pharma Holding",
      "query": "Vicore Pharma Holding AB",
      "candidate_count": 349
    },
    "period": {
      "from": "2024-08-04",
      "to": "2026-08-04",
      "years": 2
    },
    "generated_at": "2026-08-04T19:47:43Z",
    "insider": {
      "transactions": 18,
      "all_export_rows": 18,
      "acquisitions": 14,
      "disposals": 0,
      "other": 4,
      "acquisition_value_sek": 3400309.17,
      "disposal_value_sek": 0,
      "characters": {
        "Förvärv": 14,
        "Teckning": 3,
        "Tilldelning": 1
      }
    },
    "short_selling": {
      "aggregate_percent": 2.11,
      "current_public_positions": 1,
      "historical_changes": 9,
      "current_position_sum_over_0_5": 0.7
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [
    "MFN fallback: resolved_no_reports"
  ],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "vico",
      "instrument_id": "TX1937060",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/vico?id=TX1937060"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "Vicore Pharma Holding",
      "expected_name": "Vicore Pharma Holding",
      "match_score": 100.0,
      "slug": "vicore-pharma-holding",
      "url": "https://mfn.se/all/a/vicore-pharma-holding",
      "metadata": {
        "country": "Sverige",
        "list": "Mid Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Bioteknik",
        "website": "https://vicorepharma.com/"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX1937060",
      "asset_class": "SHARES",
      "isin": "SE0007577895",
      "symbol": "VICO",
      "company": "Vicore Pharma Holding",
      "market": null,
      "last_sale_price": "SEK 11.18",
      "time_as_of": "2026-08-05"
    },
    "finansinspektionen": {
      "issuer": "Vicore Pharma Holding AB",
      "lei": "549300KTNBPTZLF01130",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 13,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Vicore Pharma Holding",
      "query": "Vicore Pharma Holding AB",
      "candidate_count": 349
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a17a9a42943519ac9b9499fe483dd8fb0",
      "date": "2026-05-06",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "Delarsrapport_Q1_2026.pdf",
      "text_chars": 43334,
      "sha256": "09147e95128f9573312939d88e4cd55ef0f44869b0d6c2e67669fdb18de078a2",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 43334
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac8734d7900ed05a77157d57e58b8b371",
      "date": "2026-03-26",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "Vicore_Arsredovisning_2025.pdf",
      "text_chars": 264632,
      "sha256": "cf21b11fe94cda4920e011e4e767df699b1349e5f5e2c869b360c68369924dd6",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 177351
        },
        {
          "number": 2,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 87279
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/afd2d355616d2dcdf9003f1247ed96a80",
      "date": "2026-02-27",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "Bokslutskommunike_2025.pdf",
      "text_chars": 48919,
      "sha256": "7e4a990abee0deb5b338104e95f47947087f925b89faba7d499c506c37cc4b57",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 48919
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a29e802aad5879985f414115f16438495",
      "date": "2025-11-05",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "Delarsrapport_Q3_2025.pdf",
      "text_chars": 51972,
      "sha256": "0e5199bb265cc9be60565f6340f00d5a45b86ab1b999286b68a23102291bd697",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 51972
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a601e14263c6a6dcc72f09a601e5b2ca5",
      "date": "2025-08-22",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "Delarsrapport_Q2_2025.pdf",
      "text_chars": 46643,
      "sha256": "4f5e331a70cc9772f9dd39e6df020504fac3d16ca61251bf208d4a16873d736a",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 46643
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ad1ca81c15c657972c0cbda55b9a6cf97",
      "date": "2025-05-06",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "Delarsrapport_1_Jan_31_Mar_2025.pdf",
      "text_chars": 45176,
      "sha256": "161203666816ea945e02334a7230bae78a4e1ea2e6b137545068c9a8eaa7c3c3",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 45176
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a66794ceb802528c55ffb3b1ee8c7dc30",
      "date": "2025-03-26",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "Vicore_Arsredovisning_2024.pdf",
      "text_chars": 287791,
      "sha256": "e628a6484cb38d6916f50f4bc7eb4107854107a6b4209198279eeffc4e890f83",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 177393
        },
        {
          "number": 2,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 110396
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae73c8303818455588695b9a0c1a06058",
      "date": "2025-02-27",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "Bokslutskommunike_2024_SWE.pdf",
      "text_chars": 49883,
      "sha256": "d4ea4a7ef8edb2a85eb7b43efde15f54c7399e3b60bc62edffc2942f1effadfd",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 49883
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a5e2cc4eb1aa5dacb7918657cd4a93246",
      "date": "2024-11-05",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "Delarsrapport_Q3_2024.pdf",
      "text_chars": 50324,
      "sha256": "d71acb6909f6dc0064559b9d5eada617dc7a5aa63bb83175f56d6ad761982ba0",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 50324
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac33a252ae1cac6377103173b7acabf2c",
      "date": "2024-08-22",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "Delarsrapport_Q2_2024.pdf",
      "text_chars": 44660,
      "sha256": "b1aba9ecf5644930cba10892b99fbd6453b3cb18fcd3bba129bfe31e5a67ade5",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 44660
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aacba62192026d1de39a5f33b4daf9986",
      "date": "2024-05-03",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "Delarsrapport_Q1_2024_FINAL.pdf",
      "text_chars": 41479,
      "sha256": "4bb721d5cd96b117a2187fe95d2cbeaeb4ef1620ebcc885308a87e4feba34f5d",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 41479
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a2ae7c68718235fae332b816f53ab1738",
      "date": "2024-03-27",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "Vicore_Arsredovisning_2023.pdf",
      "text_chars": 269652,
      "sha256": "8cd42f435d0f31bff067af1f3f30fc1a7412f89d76ced868bea0929d79c6716a",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 179110
        },
        {
          "number": 2,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
          "chars": 90540
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ad4f6a640bbf90aa0f94b72149a909dbd",
      "date": "2024-02-28",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "Bokslutskommunike_2023.pdf",
      "text_chars": 45516,
      "sha256": "f652188f84d1a7e121c4fd947d8c3929e298979d50634fa8ca98838242c02eab",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 45516
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a0e437a99b9af6d9ca3735b061af97537",
      "date": "2023-11-02",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "Delarsrapport_Q3_2023.pdf",
      "text_chars": 43926,
      "sha256": "3344bafc5252080871c96ece9a38f5b51c9d7b3b10a360129f1a7bef78146d4d",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 43926
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ade8c9e5626a289c75d0d5612b408bc0b",
      "date": "2023-08-24",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "Delarsrapport_April_Juni_2023.pdf",
      "text_chars": 42123,
      "sha256": "fc851ed2d2aaaac8bab7199536d85cdbc693257f10bbf79d95a307b89d767da2",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 42123
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a4a08c7c7e1a6de7650f7cc53f699d9bf",
      "date": "2023-05-04",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "Delarsrapport_Jan_Mar_2023.pdf",
      "text_chars": 39808,
      "sha256": "8e7ec395406e329278366eab28393e92de4ec1fbc55fc025a82ed1d7356fea5b",
      "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 39808
        }
      ]
    },
    {
      "doc_id": "sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm",
      "title": "SEC filing – odaterad – tm2619347d1_ex99-1.htm",
      "source": "SEC EDGAR",
      "source_class": "sec",
      "source_url": null,
      "date": null,
      "period": null,
      "form_type": "SEC filing",
      "report_key": null,
      "filename": "tm2619347d1_ex99-1.htm",
      "text_chars": 5916,
      "sha256": "64961e5e097265ef2af1cd05b553a06c33cb301a90bc3b1e3114352b56f848ad",
      "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm",
      "txt_url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm/part-001.html",
          "chars": 5916
        }
      ]
    },
    {
      "doc_id": "sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm",
      "title": "SEC filing – odaterad – tm2619347d1_6k.htm",
      "source": "SEC EDGAR",
      "source_class": "sec",
      "source_url": null,
      "date": null,
      "period": null,
      "form_type": "SEC filing",
      "report_key": null,
      "filename": "tm2619347d1_6k.htm",
      "text_chars": 1642,
      "sha256": "a4b3c4ea3a50c3a069277d51877c56b6ba981156cf5515175e5514aefe71d333",
      "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm",
      "txt_url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm/part-001.html",
          "chars": 1642
        }
      ]
    },
    {
      "doc_id": "sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt",
      "title": "SEC filing – odaterad – 0001104659-26-080617.txt",
      "source": "SEC EDGAR",
      "source_class": "sec",
      "source_url": null,
      "date": null,
      "period": null,
      "form_type": "SEC filing",
      "report_key": null,
      "filename": "0001104659-26-080617.txt",
      "text_chars": 21251,
      "sha256": "f70272844128ed42b63a29a37ead6b976b1ec8284ef3d51f7f364c78e42d901a",
      "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt",
      "txt_url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt/part-001.html",
          "chars": 21251
        }
      ]
    },
    {
      "doc_id": "sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html",
      "title": "SEC filing – odaterad – 0001104659-26-080617-index.html",
      "source": "SEC EDGAR",
      "source_class": "sec",
      "source_url": null,
      "date": null,
      "period": null,
      "form_type": "SEC filing",
      "report_key": null,
      "filename": "0001104659-26-080617-index.html",
      "text_chars": 990,
      "sha256": "78353841bd34e4efe3f7ace681883b4f0a4912daa17b8dca12d99922e24be9b1",
      "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html",
      "txt_url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html/part-001.html",
          "chars": 990
        }
      ]
    },
    {
      "doc_id": "sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html",
      "title": "SEC filing – odaterad – 0001104659-26-080617-index-headers.html",
      "source": "SEC EDGAR",
      "source_class": "sec",
      "source_url": null,
      "date": null,
      "period": null,
      "form_type": "SEC filing",
      "report_key": null,
      "filename": "0001104659-26-080617-index-headers.html",
      "text_chars": 1362,
      "sha256": "e4a85a753604717796572d2f025716220b775cf28c8f2582fee6f3c55e6048db",
      "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html",
      "txt_url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html/part-001.html",
          "chars": 1362
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/vicore-pharma-holding",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 12640,
      "sha256": "b777bd0383a50819bc3ab3cc52dbc206b4e1ebd155990f3f22cc745d99efbe68",
      "url": "/company/vicore-pharma-holding/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/vicore-pharma-holding/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/vicore-pharma-holding/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 12640
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/vicore-pharma-holding/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/vicore-pharma-holding/market/history.json",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/vicore-pharma-holding/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/vicore-pharma-holding/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/market/instrument.json"
    },
    {
      "label": "SEC filing-manifest JSON",
      "url": "/company/vicore-pharma-holding/market/sec-manifest.json",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/market/sec-manifest.json"
    },
    {
      "label": "SEC sammanfattning JSON",
      "url": "/company/vicore-pharma-holding/market/sec-summary.json",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/market/sec-summary.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/vicore-pharma-holding/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/vicore-pharma-holding/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": true,
    "status": "retrieved",
    "captured_at": "2026-08-01T05:51:54Z",
    "view_count": 4,
    "url": "/company/vicore-pharma-holding/morningstar",
    "path": "D:\\Web\\aktieanalys\\public\\company\\.vicore-pharma-holding.tmp\\morningstar",
    "files": [
      "index.html",
      "summary.txt",
      "screenshot.png"
    ]
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/vicore-pharma-holding/finansinspektionen",
    "transaction_count": 18,
    "aggregate_short_percent": 2.11,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/vicore-pharma-holding/llms.txt",
  "json_url": "/company/vicore-pharma-holding/company.json",
  "document_index_url": "/company/vicore-pharma-holding/documents.json",
  "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding"
}